The reassertion profiles of long acting β 2-adrenoceptor agonists in the guinea pig isolated trachea and human recombinant β 2-adrenoceptor

Pulmonary Pharmacology and Therapeutics

Volumn 24, Issue 2, 2011, Pages 247-255

  Patel, S ^a   Summerhill, S ^a   Stanley, M ^a   Perros Huguet, C ^a   Trevethick, M A ^a  

^a PFIZER GLOBAL RESEARCH AND DEVELOPMENT   (United Kingdom)

Author keywords

Asthma; Bronchodilation; COPD; Formoterol; Indacaterol; Salmeterol

Indexed keywords

5 [2 [2 HYDROXY 2 (4 HYDROXY 3 HYDROXYMETHYLPHENYL)ETHYLAMINO]PROPYL] 1H INDOLE 2 CARBOXYLIC ACID 2,6 DIMETHOXYBENZYLAMIDE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; CARMOTEROL; FORMOTEROL; INDACATEROL; N ADAMANTAN 1 YL 2 [3 [2 [2 HYDROXY 2 (4 HYDROXY 3 HYDROXYMETHYLPHENYL)ETHYLAMINO]PROPYL]PHENYL]ACETAMIDE; PF 610355; PF 613322; SALMETEROL; SOTALOL; UK 503590; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CHO CELL; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DETERMINATION; DRUG POTENCY; DRUG RECEPTOR BINDING; ELECTRIC FIELD; GUINEA PIG; HUMAN; HUMAN CELL; MALE; NONHUMAN; PRIORITY JOURNAL; TRACHEA;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; ALBUTEROL; ANIMALS; BRONCHODILATOR AGENTS; CHO CELLS; CRICETINAE; CRICETULUS; ETHANOLAMINES; GUINEA PIGS; HUMANS; MALE; PROTEIN BINDING; RECEPTORS, ADRENERGIC, BETA-2; TIME FACTORS; TRACHEA;

EID: 79951943071     PISSN: 10945539     EISSN: 15229629     Source Type: Journal    
DOI: 10.1016/j.pupt.2010.11.004     Document Type: Article

References (36)

1. Chung K.F., Caramori G., Adcock I.M. Inhaled corticosteroids as combination therapy with beta-adrenergic agonists in airways disease: present and future. Eur J Clin Pharmacol 2009, 65:853-871.
2. Tashkin D.P. Indacaterol maleate for the treatment of chronic obstructive pulmonary disease. Expert Opin Pharmacother 2010, 11:2077-2085.
3. Anderson G.P., Lindén A., Rabe K.F. Why are long-acting beta-adrenoceptor agonists long-acting?. Eur Respir J 1994, 7:569-578.
4. Coleman R.A., Johnson M., Nials A.T. Vardey CJ.Exosites: their current status, and their relevance to the duration of action of long-acting beta 2-adrenoceptor agonists. Trends Pharmacol Sci 1996, 17:324-330.
5. Johnson M., Butchers P.R., Coleman R.A., Nials A.T., Strong P., Sumner M.J., et al. The pharmacology of salmeterol. Life Sci 1993, 52:2131-2143.
6. Cazzola M., Segreti A., Matera M.G. Novel bronchodilators in asthma. Curr Opin Pulm Med 2010, 16:6-12.
7. Baur F., Beattie D., Beer D., Bentley D., Bradley M., Bruce I., et al. The identification of indacaterol as an ultralong-acting inhaled beta2-adrenoceptor agonist. JMed Chem 2010, 53:3675-3684.
8. 2 adrenoreceptor agonist, PF-00610355. Eur Respir J 2009, 344S:P2017.
9. 2-adrenoceptor agonists. Bioorg Med Chem Lett 2008, 18:1280-1283.
10. Glossop P.A., Lane C.A.L., Price D.A., Bunnage M.E., Lewthwaite R.A., James K., et al. Inhalation by design: novel ultra-long-acting β2-adrenoceptor agonists for inhaled once-daily treatment of asthma and chronic obstructive pulmonary disease that utilize a sulphonamide agonist headgroup. J Med Chem 2010, 53:6640-6652.
11. Coleman R.A., Nials A.T. Novel and versatile superfusion system. Its use in the evaluation of some spasmogenic and spasmolytic agents using guinea-pig isolated tracheal smooth muscle. J Pharmacol Methods 1989, 21:71-86.
12. 2 adrenoceptors. J Pharmacol Toxicol Methods 2008, 58:189-197.
13. 2 adrenoceptor agonist with superior potency and duration of action (DoA) to salmeterol in the conscious dog model of bronchoconstriction. Eur Respir J 2009, 34:P2020.
14. 2-agonist carmoterol following 7 days once daily dosing: comparison with twice daily formoterol in patients with persistent asthma. Eur Respir J 2006, 28:665s.
15. Nials A.T., Sumner M.J., Johnson M., Coleman R.A. Investigations into factors determining the duration of action of the β2-adrenoceptor agonist, salmeterol. Br J Pharmacol 1993, 108:507-515.
16. 2 adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther 2006, 317:762-770.
17. 2-adrenoceptor agonist, TA-2005. Eur J Pharmacol 1992, 227:403-409.
18. 2-adrenoceptor activity. Bioorg Med Chem Lett 2004, 14:4705-4710.
19. Coleman R.A. On the mechanism of the persistent action of salmeterol: what is the current position?. Br J Pharmacol 2009, 158:180-182.
20. 2-adrenergic receptor. J Biol Chem 1996, 271:24029-24035.
21. Green S.A., Rathz D.A., Schuster A.J., Liggett S.B. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 2001, 421:141-147.
22. 125)I]iodoazidosalmeterol. Biochemistry 1999, 38:11278-11286.
23. Austin R.P., Barton P., Bonnert R.V., Brown R.C., Cage P.A., Cheshire D.R., et al. QSAR and the rational design of long-acting dual D2-receptor/beta 2-adrenoceptor agonists. J Med Chem 2003, 46:3210-3220.
24. Bergendal A., Lindén A., Skoogh B.E., Gerspacher M., Anderson G.P., Löfdahl C.G. Extent of salmeterol-mediated reassertion of relaxation in guinea-pig trachea pretreated with aliphatic side chain structural analogues. Br J Pharmacol 1996, 117:1009-1015.
25. Teschemacher A., Lemoine H. Kinetic analysis of drug-receptor interactions of long-acting beta2 sympathomimetics in isolated receptor membranes: evidence against prolonged effects of salmeterol and formoterol on receptor-coupled adenylyl cyclase. J Pharmacol Exp Ther 1999, 288:1084-1092.
26. Mason R.P., Rhodes D.G., Herbette L.G. Re-evaluating equilibrium and kinetic binding parameters for lipophilic drugs based on a structural model for drug interaction with biological membranes. J Med Chem 1991, 34:869-877.
27. Lombardi D., Cuenoud B., Krämer S.D. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacological properties?. Eur J Pharm Sci 2009, 38:533-547.
28. Herbette L.G., Trumbore M., Chester D.W., Katz A.M. Possible molecular basis for the pharmacokinetics and pharmacodynamics of three membrane-active drugs: propranolol, nimodipine and amiodarone. J Mol Cell Cardiol 1988, 20:373-378.
29. 2 adrenoceptors in C6 glioma cells. Mol Pharmacol 1996, 49:927-937.
30. Hanson M.A., Cherezov V., Griffith M.T., Roth C.B., Jaakola V.P., Chien E.Y., et al. A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. Structure 2008, 16:897-905.
31. Hanson M.A., Stevens R.C. Discovery of new GPCR biology: one receptor structure at a time. Structure 2009, 17:8-14.
32. Gosens R., Mutawe M., Martin S., Basu S., Bos S.T., Tran T., et al. Caveolae and caveolins in the respiratory system. Curr Mol Med 2008, 8:741-753.
33. Patel H.H., Murray F., Insel P.A. G-protein-coupled receptor-signaling components in membrane raft and caveolae microdomains. Handb Exp Pharmacol 2008, 186:167-184.
34. DiPilato L.M., Zhang J. The role of membrane microdomains in shaping beta2-adrenergic receptor-mediated cAMP dynamics. Mol Biosyst 2009, 5:832-837.
35. Szczuka A., Wennerberg M., Packeu A., Vauquelin G. Molecular mechanisms for the persistent bronchodilatory effect of the beta2-adrenoceptor agonist salmeterol. Br J Pharmacol 2009, 158:183-194.
36. 2 adrenergic receptor complexes in cardiomyocyte caveolae/rafts. J Mol Cell Cardiol 2004, 37:407-415.